HALOZYME THERAPEUTICS, INC. - Common Stock (HALO)

Q3 2018 13F Holders as of 30 Sep 2018

Type / Class
Equity / Common Stock
Shares outstanding
123,650,000
Total 13F shares
122,639,238
Share change
+290,101
Total reported value
$2,228,291,177
Put/Call ratio
56%
Price per share
$18.17
Number of holders
191
Value change
+$6,384,296
Number of buys
83
Number of sells
83

Institutional Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q3 2018

As of 30 Sep 2018, HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) was held by 191 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 122,639,238 shares. The largest 10 holders included Third Security, LLC, Vanguard Group Inc, BlackRock Inc., IRIDIAN ASSET MANAGEMENT LLC/CT, BB BIOTECH AG, STATE STREET CORP, Invesco Ltd., JPMORGAN CHASE & CO, PICTET ASSET MANAGEMENT LTD, and Thrivent Financial for Lutherans. This page lists 191 institutional shareholders reporting positions in this security for the Q3 2018 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.